

5<sup>TH</sup> EDITION

30<sup>th</sup> Nov & 1<sup>st</sup> Dec 2016

LILLE, FRANCE



**Biofit**

FOSTERING  
INNOVATION  
& TRANSFER

***A 360° approach  
to source early  
stage innovations  
in Life Sciences***

AGENDA

ORGANISED BY



IN COLLABORATION WITH



WITH THE SUPPORT OF




# ABOUT BIOFIT 2016



**1,300**  
DELEGATES



**900**  
ORGANISATIONS



**50%**  
INTERNATIONAL  
ACTORS

**30+**  
COUNTRIES  
REPRESENTED



**100**  
EXHIBITORS



**5**  
HOSTED EVENTS

**30+**

one-to-one meetings  
per participant over  
2 days

**11**

conferences  
and roundtable  
discussions

**60**

high-level  
international  
speakers

**800**

licensing  
opportunities  
(in 2015)

# STEERING COMMITTEE

## PHARMAS, BIOTECHS



**Zeina ANTOUN**  
CLINICAL RESEARCH DIRECTOR,  
**GSK - GLAXOSMITHKLINE** [FR]



**Maria BOBADILLA**  
SENIOR DIRECTOR, EXTENDING  
INNOVATION NETWORK,  
**ROCHE** [CH]



**Adrian CARTER**  
CORPORATE VICE PRESIDENT AND  
GLOBAL HEAD OF DISCOVERY  
RESEARCH COORDINATION,  
**BOEHRINGER INGELHEIM** [DE]



**Sami CHTOUROU**  
DIRECTOR OF TECHNOLOGY  
PLATFORMS AND INNOVATION,  
**LFB** [FR]



**Florence DAL DEGAN**  
R&D INNOVATION SOURCING  
DIRECTOR, **NOVO NORDISK** [DK]



**Isabelle DIEUZY-LABAYE**  
FORMER DIRECTOR, STRATEGIC  
ALLIANCES, **ZOETIS** [FR]



**Guy HELIN**  
CEO, **SYNGULON** [BE]



**Sarah HOLLAND**  
HEAD OF EUROPE, EXTERNAL  
SCIENCE & PARTNERING,  
**SANOI** [FR]



**Stephan LENSKEY**  
CHIEF OPERATING AND CHIEF  
BUSINESS OFFICE, **EPIMAB**  
**BIOTHERAPEUTICS** [CN]



**Sabrina LESAGE**  
STRATEGIC ALLIANCES MANAGER,  
**PFIZER** [FR]



**Frédéric SCAEROU**  
DIRECTOR, SCIENTIFIC  
AFFAIRS ONCOLOGY,  
**IPSEN INNOVATION** [FR]

## ACADEMIA, TTOs



**Hervé ANSANAY**  
OPERATIONS DIRECTOR,  
**SATT AXLR** [FR]



**Ivan BAINES**  
CHIEF OPERATING OFFICER,  
**MAX PLANCK INSTITUTE OF**  
**MOLECULAR CELL BIOLOGY AND**  
**GENETICS** [DE]



**Garold BREIT**  
PRINCIPAL, **BREIT IDEAS** [USA]



**Nicolas CARBONI**  
PRESIDENT, **SATT CONECTUS**  
**ALSACE** [FR]



**Jean-Luc CHAGNAUD**  
HEALTHCARE BUSINESS  
DEVELOPMENT MANAGER  
& INTELLECTUAL PROPERTY  
MANAGER, **AQUITAINE SCIENCE**  
**TRANSFERT** [FR]



**Matthieu FISICHELLA**  
LIFE SCIENCES EXPERT,  
**SATT NORD** [FR]



**Esther LANGE**  
INDUSTRY LIAISON MANAGER,  
**ASCENION** [DE]

## ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMS



**Christian POLICARD**  
MEMBER OF THE BOARD,  
CHAIRMAN OF THE BUSINESS  
DEVELOPMENT SUB-COMMITTEE,  
**FRANCE BIOTECH** [FR]



**Claude-Alain CUDENNEC**  
GENERAL DIRECTOR, **AFSSI -**  
**FRENCH ASSOCIATION**  
**OF OUTSOURCING AND**  
**INNOVATIVE COMPANIES** [FR]



**Marco FIORINI**  
GENERAL SECRETARY, **AVIESAN -**  
**FRENCH NATIONAL ALLIANCE FOR**  
**LIFE SCIENCES AND HEALTH** [FR]



**Barbara FREISCHEM**  
MANAGING DIRECTOR, **EBE -**  
**EUROPEAN BIOPHARMACEUTICAL**  
**ENTERPRISES** [BE]



**Didier FROMMWEILER**  
GENERAL MANAGER,  
**ALSACE BIOVALLEY** [FR]



**Sara NUNEZ-GARCIA**  
SENIOR ASSOCIATE,  
**SOFINNOVA PARTNERS** [FR]



**Emilie ROYER**  
DIRECTOR, **EUROBIOMED** [FR]





**Cécile THEARD-JALLU**  
PARTNER ATTORNEY, **DE GAULLE**  
**FLEURANCE & ASSOCIÉS** [FR]



**Etienne VERVAECKE**  
GENERAL MANAGER,  
**EURASANTE & NHL CLUSTER** [FR]

# PARTNERING

**48 hours** to meet your future project partners  
and accelerate innovation



Partnering at BioFIT is powered by **partneringONE®**

a product of **EBD**GROUP

# PRESENTATION SESSIONS

## *The early stage innovations you need*

The BioFIT presentation sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development opportunities in the Life Sciences sector.

### Science Slams

Discover the  
innovative R&D  
projects stemming  
from academia

### Licensing Opportunity Presentations\*

Discover the best  
“ready to be licensed”  
technologies from TTOs  
and related structures

These technologies will be related  
to the following areas: **Oncology**,  
**Neurology**, **Cardiology**,  
**Infectiology** and **Vaccines**

### Start-up Slams

Discover the most  
innovative start-ups  
(≤ 3 years old or about  
to be created)

**SATT**  
Réseau  
Tech Transfer  
Accelerator Network

\*Organised in partnership with  
TechnoMarket Life Sciences,  
an event organised by Réseau SATT



# CONFERENCE PROGRAMME

## Track 1

### ***Best practices in collaborative research***

---

## Track 2

### ***Key issues in licensing and tech transfer***

---

## Track 3

### ***Funding early stage innovation***

#### Plenary Session



#### KEYNOTE

#### **PETER GRUSS**

« Academic-/ biotech-/pharma-cooperations require new models »

#### PANEL DISCUSSION

### ***Is Europe competitive enough in Life Sciences innovation?***

MODERATOR:

**John Carroll**

EDITOR, **ENDPOINTS** 

**Piyush Unalkat**

HEAD OF TECHNOLOGY TRANSFER INVESTMENTS,  
INNOVATION & TECHNOLOGY INVESTMENTS,  
EUROPEAN INVESTMENT FUND 

**Ron Newbold**

VP EXTERNAL R&D INNOVATION,  
**PFIZER WORLDWIDE RESEARCH & DEVELOPMENT** 





# SPEAKERS


## Paul Ashley

DEPUTY HEAD OF TECH TRANSFER,  
ISIS INNOVATION 

## Magnus Björnsne

CEO, ASTRAZENCA BIOVENTUREHUB 

## Jasper Bos

VICE PRESIDENT HEALTHCARE,  
MERCK VENTURES 


## Nicolas Carboni

PRESIDENT, SATT CONECTUS ALSACE 

## John Carroll

EDITOR, ENDPOINTS 

## Sam Fazeli

HEAD OF BLOOMBERG INTELLIGENCE,  
EMEA; SENIOR PHARMACEUTICAL ANALYST,  
BLOOMBERG INTELLIGENCE 

## Roberto Gradnik

CEO, IXALTIS 

## Daniel Green

CEO, YAQRIT 

## Peter Gruss

EX CEO, MAX PLANCK SOCIETY 

## Christophe Guichard

DIRECTOR, ECLOSION 

## Frank Hensel

INVESTMENT MANAGER,  
HIGH-TECH GRÜNDERFONDS 

## Thierry Laugel

MANAGING PARTNER,  
KURMA PARTNERS 

## Sabine Louet

EDITOR, EUROSCIENTIST 


## Nicolas Marro

EUROPEAN PATENT ATTORNEY,  
BEAU DE LOMÉNIE 

## Soren Moller

MANAGING PARTNER, NOVO SEEDS 

## Philippe Monteyne

VC PARTNER, FUND+ 

## Ron Newbold

VP EXTERNAL R&D INNOVATION,  
PFIZER WORLDWIDE RESEARCH  
& DEVELOPMENT 

## Stefan K. Nilsson

CEO, LIPIGON 


## Michèle Ollier

PARTNER AND COFOUNDER,  
MEDICXI VENTURES 

## Katja Rosenkranz

PRINCIPAL, V-BIO VENTURES 

## Kees de Ruig

BUSINESS DEVELOPMENT MANAGER,  
EATRIS 

## Kai Simons

CEO LIPOTYPE & DIRECTOR EMERITUS  
OF THE MAX PLANCK SOCIETY 


## Tzachy Tal

DIRECTOR BD, TECHNION 


## Cecile Théard-Jallu

PARTNER, DE GAULLE FLEURANCE  
& ASSOCIÉS 

## Iain Thomas

HEAD OF LIFE SCIENCES,  
CAMBRIDGE ENTERPRISE 

## Piyush Unalkat

PRINCIPAL OF EQUITY INVESTMENTS  
AND HEAD OF TECHNOLOGY TRANSFER  
& IP INVESTMENTS,  
ITI EUROPEAN INVESTMENT FUND 

## Charles Woler






CEO, BIOMNIS 

## Einat Zisman

CEO, FUTURX 

# DAY ONE






## Wednesday 30<sup>th</sup> November

	TRACK 1 Best practices in collaborative research	TRACK 2 Key issues in licensing and tech transfer	TRACK 3 Funding early stage innovation	Presentation sessions & TechnoMarket by Réseau SATT	Business Convention	Hosted events
8.30 am 9.30 am	REGISTRATION AND WELCOME					
9.30 am 11.00 am			Committed to the VC business: Why and how universities are involved in new venture funds?	Licensing Opportunities and TechnoMarket  10 slots	 One- to-one meetings	IDEA Summit
11.00 am 11.30 am	COFFEE BREAK					BREAK
11.30 am 1.00 pm	KEYNOTE Peter Gruss		PLENARY SESSION		PANEL DISCUSSION Is Europe competitive enough in Life Sciences innovation?	
1.00 pm 2.30 pm	LUNCH					LUNCH
2.30 pm 4.00 pm		What is the best background for an academic spin-off CEO?	How to create a European seed capital market?	Science slams  7 slots		IDEA Summit
4.00 pm 4.30 pm	POSTER EXHIBITION AND NETWORKING BREAK					BREAK
4.30 pm 5.15 pm		WORKSHOPS Could your innovations be protected efficiently by tools other than patents?	Part 1: Lessons learned: Dos & don't from experienced entrepreneurs		 One- to-one meetings	IDEA Summit
5.15 pm 6.00 pm		- What about regulatory data protection, trade secret, blockchain & smart contracts?	Part 2: How can former successful entrepreneurs become involved and support today's life sciences start-ups?	Licensing Opportunities and TechnoMarket  10 slots		
7.00 pm	BIOPARTY / NETWORKING EVENING					



# DAY TWO

Thursday 1<sup>st</sup> December

	TRACK 1 Best practices in collaborative research	TRACK 2 Key issues in licensing and tech transfer	TRACK 3 Funding early stage innovation	Presentation sessions & TechnoMarket by Réseau SATT	Business Convention	Hosted events	
8.30 am 9.30 am	REGISTRATION AND WELCOME						
9.30 am 11.00 am	How can industry and investor incubator models accelerate research translation?			Licensing Opportunities and TechnoMarket  10 slots	 One- to-one meetings	SIRIC ONCO Lille Days	
11.00 am 11.30 am	POSTER EXHIBITION AND NETWORKING BREAK					BREAK	
11.30 am 1.00 pm		Are universities a short-term or long term partner for spin-offs?	How to spark the interest of VCs for Series A financing?	Start-up slams  7 slots		SIRIC ONCO Lille Days	
1.00 pm 2.30 pm	LUNCH					LUNCH	
2.30 pm 4.00 pm		To spin or not to spin?		Licensing Opportunities and TechnoMarket  10 slots		SIRIC ONCO Lille Days	
4.00 pm 5.00 pm	How can the deal- making process be accelerated by standard elements and framework agreements?			Start-up slams  5 slots			
5.00 pm 6.00 pm	NETWORKING BREAK / CLOSING REMARKS						

# HOSTED EVENTS BY **Biofit**



29<sup>th</sup> Nov

Organised by AFSSI, the French Association of Outsourcing and Innovative Companies, the AFSSI conference gathers over 100 French entrepreneurs from R&D, life sciences, big company decision makers, academic research leaders, governmental regulators and investors to discuss the best relationships within the new landscape of industry R&D cooperation.

The conference will focus on the growing number of small and medium technology companies driven by the needs of biopharma companies to optimise research costs and of academia to advance research programmes to maturity.

[www.afssi.fr/conference](http://www.afssi.fr/conference)



30<sup>th</sup> Nov  
1<sup>st</sup> Dec

TechnoMarket is an event created by Réseau SATT to discover innovative technologies from public research. It is a real market place for companies ready to innovate. The technologies presented will be selected by an expert committee with a call for applications stemming from French and European transfer structures.

\* Activity organised in partnership with BioFIT Licensing Opportunity Presentations

ORGANISED BY



## INNOVATION IN CARDIOMETABOLIC DISEASES



29<sup>th</sup> Nov  
30<sup>th</sup> Nov

Organised by EGID, the European Genomic Institute for Diabetes, the 4<sup>th</sup> edition of the EGID Symposium is hosted by BioFIT and organised in collaboration with IDEA Summit.

The Steering Committee and speakers – world leaders in their fields – will present the latest scientific advances in diabetes and related disorders. This year, EGID Symposium is about “Liver, Diabetes and Cardiovascular Risks”.

This symposium provides an opportunity for young researchers to present their work during poster presentations and to win the «Best Poster Award» (€1,000).

[www.egid.fr](http://www.egid.fr)

Discover innovative technologies during 2 days of pitch presentations and poster exhibition dealing with **ONCOLOGY, INFECTIOLOGY AND VACCINES, CARDIOLOGY, NEUROLOGY** and schedule B-to-B appointments to meet, exchange and deepen the addressed issues.

[www.technomarket.fr](http://www.technomarket.fr)

## INNOVATION IN DIABETES

# IDEA Summit

LILLE - 2016

30<sup>th</sup> Nov  
1<sup>st</sup> Dec

This 4<sup>th</sup> edition of the IDEA Summit is organised by Lund University Diabetes Center, Eurasanté and the Nutrition Health Longevity cluster, and supported by Ascenion, AstraZeneca, Novo Nordisk and Sanofi, in collaboration with BioFIT Event and EGID Symposium.

The IDEA Summit is a unique European event dedicated to collaborative research and to technology transfer in the field of diabetes.

The summit aims to be a platform for dialogue and to strengthen the links between academia and industry.

At previous editions of the IDEA Summit, academia and industry enhanced their understanding of each other's strengths and driving forces. However, there is still a significant need to develop new ways of stimulating interaction and sharing knowledge and resources more effectively.

The organisers want to go even further by involving patients and creating long-term links between academia and industry.

[www.idea-summit-diabetes.com](http://www.idea-summit-diabetes.com)

ORGANISED BY



SPONSORED BY



## INNOVATION IN ONCOLOGY

# ONCO LILLE DAYS

From Science to Care

30<sup>th</sup> Nov  
1<sup>st</sup> Dec

Organised by SIRIC ONCOLille, an Integrated Cancer research consortium in Lille supporting clinicians and researchers in the field of oncology, ONCOLille Days feature a programme of conferences and poster presentations around oncology. The translational research consortium ONCOLille is promoting a swift transfer between basic and clinical researches in the Lille area on two major issues of modern oncology: the tumor resistance to loco-regional treatments and the tumor dormancy (or resilience) after remission.

During the scientific symposium, the SIRIC ONCOLille Days, researchers will present their latest discoveries on the molecular mechanisms explaining the tumor cell resistance to treatment (MET receptors, MUC4-ErbB2 complexes, calcium canals involvement, immunosuppressive role of regulatory T cells...) or explaining cancer cell persistence after treatment (immune-evasion due to PD1-PDL1 interactions, tumor cell clonality...). Drug development strategies based on those findings will be discussed.

[www.oncolille.fr](http://www.oncolille.fr)

ORGANISED BY



# HOSTED EVENTS PROGRAMME



**Biofit**



	29 <sup>th</sup> Nov	29 <sup>th</sup> Nov	30 <sup>th</sup> Nov	1 <sup>st</sup> Dec
8.30 am	Registration & welcome	Registration & welcome	Registration & welcome	
9.30 am	Highlighting AFSSI Members’ (life sciences R&D service providers) solid and complementary expertise	Post-translational protein modifications as a novel mechanism of hepatic fibrosis	Pitches and posters	Pitches and posters
10.00 am		Fatty liver, lipoprotein metabolism and cardiovascular risk		
10.20 am				
10.30 am				
10.40 am				
11.00 am	Break	Hepatic Steatosis	Break	Poster exhibition & networking break
11.30 am		Poster presentations	BioFIT Plenary Session	BioFIT Start-up slams
12.00 pm				
12.30 pm				
1.00 pm				
2.00 pm				
2.30 pm	Lunch	Lunch	Lunch	
3.00 pm	Building sustainable relationships between industrial life sciences R&D stakeholders	Alterations in DNA methylation and type 2 diabetes	BioFIT Science slams	Pitches and posters
3.30 pm		Histological classification of NAFLD: limits and perspectives		
4.00 pm		Molecular mechanisms of liver fibrosis (title to be confirmed)		
4.30 pm		Best Paper Award		
5.00 pm		Conclusions		
5.30 pm	Benchmarking similar European R&D provider networks		Pitches and posters	
6.00 pm				

	30 <sup>th</sup> Nov	1 <sup>st</sup> Dec	30 <sup>th</sup> Nov	1 <sup>st</sup> Dec
8.30 am ...	Registration & welcome		Registration & welcome	
9.30 am ...				
10.00 am ...				
10.20 am ...	Are the metabolic syndrome and insulin resistance a breaking ground for innovation?			Innovative therapies against tumor resistance and dormancy  x 5 10.20
10.30 am ...				
10.40 am ...		Partnering during BioFIT	Partnering during BioFIT	
11.00 am ...				Innovative tools and pre-clinical models  x 1
11.30 am ...	Break			Break
12.00 pm ...	BioFIT Plenary Session		BioFIT Plenary Session	Innovative tools and pre-clinical models  x 4
12.30 pm ...				
1.00 pm ...				
2.00 pm ...	Lunch		Lunch	Lunch
2.30 pm ...				
2.50 pm ...	What are pharma's needs in terms of licensing and collaborative research in diabetes?	Partnering during BioFIT		Innovative tools and pre-clinical models  x 1
3.30 pm ...				Human and social sciences  x 2
4.00 pm ...				Clinical investigations  x 1
4.30 pm ...	Break		Partnering during BioFIT	
5.00 pm ...	5 minutes to persuade (research projects & start-up pitches)			ONCOLILLE 2  x 1
5.30 pm ...	Most successful & innovative start-ups in diabetes in 2015/2016			Strategic Workshop
6.00 pm ...				

# REGISTER NOW FOR BIOFIT 2016





## **REGISTRATION FEES** (excl. VAT)

<b>Mature company</b> (> 3 years old) .....	€ 1,199
<b>TTO   Research Institute   Cluster   Association</b> .....	€ 1,019
<b>Emerging company</b> (≤ 3 years old) or <b>SME</b> (≤ 5 employees) .....	€ 479
<b>Academic scientist</b> .....	€ 399

## **EXHIBITION FEES** (excl. VAT)

*As an exhibitor, you will gain high visibility with the leaders in the Life Sciences field.*

**Equipped booths:**

 6 m <sup>2</sup>	 9 m <sup>2</sup>	 12 m <sup>2</sup>	 18 m <sup>2</sup>
€ 2,200	€ 3,300	€ 4,400	€ 6,600

## **SPONSORSHIP OPPORTUNITIES** (excl. VAT)

*Discover our sponsorship opportunities and maximise your presence:*



**Gold Sponsor**  
€ 15,000



**Silver Sponsor**  
€ 9,000



**Bronze Sponsor**  
€ 6,000

**There are many additional  
visibility opportunities,  
please contact us for more  
information.**

# THEY SUPPORT US

## SILVER SPONSOR



## BRONZE SPONSORS



Boehringer  
Ingelheim



Cabinet Beau de Loménie



DE GAULLE  
FLEURANCE  
& ASSOCIÉS  
SOCIÉTÉ D'AVOCATS



inpi  
INSTITUT NATIONAL  
DE LA PROPRIÉTÉ  
INDUSTRIELLE



LFB  
ETHICAL COMMITMENT



PHARMA  
LOGISTICS  
CLUB



SATT  
Recherche  
Les Sociétés d'Accélération  
du Transfert de Technologies

## MAIN SUPPORTERS



Sciences de la Vie  
AFSSI  
Association Française  
des Sociétés de Services et d'Innovation



Alsace  
BioValley



ATLANPOLE  
biotherapies  
Thinking up tomorrow's medicine



BIO BARQUES  
BIOLOGICAL INNOVATION, MANAGEMENT  
AND COMMUNICATION



biogal



BioGateway



Biotechnologies  
France



CPI  
CONSEILS  
EN PROPRIÉTÉ  
INDUSTRIELLE



CzechBio



france  
biotech  
association française  
des entrepreneurs  
en sciences de la vie



medicallips



medicen  
Innovation  
for people



FRANCHE-COMTE / FRANCE  
Pôle des  
microtechniques  
Inside everything



TEMIS  
TECHNOLOGICAL AND MEDICAL INNOVATION - A. TAILLE



the assets

## SUPPORTERS



ascenion



asebio  
SPANISH BIOTECHNOLOGY ASSOCIATION



BIA  
UK Biotechnology Association



biocat



BioM



bionow



BioPartner



DANISH  
DIABETES ACADEMY



enterprise  
EUROPEAN



EuropaBio  
The European Association for Biotechnology



FlandersBio  
BUILDING BIOTECH BRIDGES



Holland  
BIO



innoget  
Oxfordshire partnership



JBA  
Japan Biotechnology Association



LBTA  
LIFE SCIENCE TECHNOLOGY ASSOCIATION



MediWales



obn



one  
nucleus



P-BIO



sweden BIO  
The Swedish Life Science Network Organisation



SWISS  
BIOTECH  
National Thematic Network



WORLD  
CEBISITY

## MEDIA PARTNERS



actulabo



ArgosBioTech



BIOTECH  
GATE



European  
Biotechnology  
Life Sciences and Industry Magazine



european  
pharmaceutical



GIT  
LABORATORY  
JOURNAL  
EUROPE



GlobalData



INNOVATION  
Review



iptechex  
pharmaceuticals



La gazette  
DU LABORATOIRE



LABIOTECH.eu  
The European Biotech News Website



Life Sciences  
Serie



MedNexus  
Specialties in Evidence Medicine Innovation



|transkript





EVENT VENUE

**Lille Grand Palais**

**1 Boulevard des Cités Unies  
59777 Lille - France**

**[www.biofit-event.com](http://www.biofit-event.com)**



**@BIOFIT\_EVENT**

## CONTACTS

**Margaux Satola**

Business Development Manager

[msatola@eurasante.com](mailto:msatola@eurasante.com)

+33 (0)3 59 39 01 82

**Claire Lesnik**

Conference Officer

[clesnik@eurasante.com](mailto:clesnik@eurasante.com)

+33 (0)3 59 39 01 87

design: cndicegras.com

### **Lille is located at the crossroads of four major European capitals.**

This location is a strategic asset, positioning Lille at the centre of the most heavily populated and richest area in Europe.


The region is the third most attractive in France in terms of real estate costs. In Europe, the city of Lille is ranked number in terms of best operating costs.

The local health sector is a key part of the regional economy:

**1,000+ COMPANIES**

**28,500+ EMPLOYEES**

**A €11.3 BILLION TURNOVER**



## INSTITUTIONAL PARTNERS

